A new approach

Animal and clinical pharmacology of zafirlukast (Accolate®, ICI-204,219)

William Calhoun, Jr Virchow J.Chr.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Zafirlukast (Accolate®, ICI-204,219) is a potent and selective antagonist of cysteinyl leukotriene receptors in several animal species, as well as in pulmonary tissues from humans. In animals, it inhibits leukotriene- and antigen-induced bronchoconstriction, plasma extravasation in pulmonary tissue, and eosinophil accumulation in lungs, and attenuates late phase bronchoconstriction and airway hyperresponsiveness following antigen inhalation. In humans, zafirlukast is well absorbed following oral administration, with peak plasma concentrations achieved approximately 3 h postdose. The half-life of zafirlukast is 10 h, with steady-state concentrations achieved within 3 days of twice daily dosing. Orally administered zafirlukast decreases the bronchoconstrictor effect of inhaled leukotriene D4 (LTD4) in a dose-dependent manner, and reduces the bronchoconstriction induced by cold air, sulphur dioxide, platelet-activating factor or exercise in asthmatic patients. Compared with placebo, zafirlukast reduced allergen-induced bronchoconstriction and the associated bronchial hyperresponsiveness. The action of zafirlukast on the airways has characteristic suggesting it is an antiinflammatory drug. In an initial placebo-controlled study, zafirlukast significantly reduced the cellular infiltrate 48 h after segmental allergen challenge, and reduced superoxide production from purified alveolar macrophages and tumour necrosis factor (TNF)-α concentrations in bronchoalveolar lavage fluid. The pharmacological profile of zafirlukast indicates that it prevents the airflow restriction resulting from bron-choconstriction and other inflammatory changes in the airways and, thus, could be useful as a preventative drug in the management of asthma.

Original languageEnglish (US)
Pages (from-to)264-268
Number of pages5
JournalEuropean Respiratory Review
Volume7
Issue number46
StatePublished - 1997
Externally publishedYes

Fingerprint

Clinical Pharmacology
Bronchoconstriction
Lung
Allergens
Placebos
zafirlukast
Bronchoconstrictor Agents
Leukotriene D4
Antigens
Sulfur Dioxide
Leukotrienes
Platelet Activating Factor
Bronchoalveolar Lavage Fluid
Alveolar Macrophages
Eosinophils
Superoxides
Pharmaceutical Preparations
Inhalation
Oral Administration
Half-Life

Keywords

  • Airway responsiveness
  • Anti-inflammatory
  • Eosinophils
  • Late asthmatic response
  • Leukotriene antagonists
  • Zafirlukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

A new approach : Animal and clinical pharmacology of zafirlukast (Accolate®, ICI-204,219). / Calhoun, William; Virchow J.Chr., Jr.

In: European Respiratory Review, Vol. 7, No. 46, 1997, p. 264-268.

Research output: Contribution to journalArticle

@article{27f73a5607f1495991831b276af9adf4,
title = "A new approach: Animal and clinical pharmacology of zafirlukast (Accolate{\circledR}, ICI-204,219)",
abstract = "Zafirlukast (Accolate{\circledR}, ICI-204,219) is a potent and selective antagonist of cysteinyl leukotriene receptors in several animal species, as well as in pulmonary tissues from humans. In animals, it inhibits leukotriene- and antigen-induced bronchoconstriction, plasma extravasation in pulmonary tissue, and eosinophil accumulation in lungs, and attenuates late phase bronchoconstriction and airway hyperresponsiveness following antigen inhalation. In humans, zafirlukast is well absorbed following oral administration, with peak plasma concentrations achieved approximately 3 h postdose. The half-life of zafirlukast is 10 h, with steady-state concentrations achieved within 3 days of twice daily dosing. Orally administered zafirlukast decreases the bronchoconstrictor effect of inhaled leukotriene D4 (LTD4) in a dose-dependent manner, and reduces the bronchoconstriction induced by cold air, sulphur dioxide, platelet-activating factor or exercise in asthmatic patients. Compared with placebo, zafirlukast reduced allergen-induced bronchoconstriction and the associated bronchial hyperresponsiveness. The action of zafirlukast on the airways has characteristic suggesting it is an antiinflammatory drug. In an initial placebo-controlled study, zafirlukast significantly reduced the cellular infiltrate 48 h after segmental allergen challenge, and reduced superoxide production from purified alveolar macrophages and tumour necrosis factor (TNF)-α concentrations in bronchoalveolar lavage fluid. The pharmacological profile of zafirlukast indicates that it prevents the airflow restriction resulting from bron-choconstriction and other inflammatory changes in the airways and, thus, could be useful as a preventative drug in the management of asthma.",
keywords = "Airway responsiveness, Anti-inflammatory, Eosinophils, Late asthmatic response, Leukotriene antagonists, Zafirlukast",
author = "William Calhoun and {Virchow J.Chr.}, Jr",
year = "1997",
language = "English (US)",
volume = "7",
pages = "264--268",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "46",

}

TY - JOUR

T1 - A new approach

T2 - Animal and clinical pharmacology of zafirlukast (Accolate®, ICI-204,219)

AU - Calhoun, William

AU - Virchow J.Chr., Jr

PY - 1997

Y1 - 1997

N2 - Zafirlukast (Accolate®, ICI-204,219) is a potent and selective antagonist of cysteinyl leukotriene receptors in several animal species, as well as in pulmonary tissues from humans. In animals, it inhibits leukotriene- and antigen-induced bronchoconstriction, plasma extravasation in pulmonary tissue, and eosinophil accumulation in lungs, and attenuates late phase bronchoconstriction and airway hyperresponsiveness following antigen inhalation. In humans, zafirlukast is well absorbed following oral administration, with peak plasma concentrations achieved approximately 3 h postdose. The half-life of zafirlukast is 10 h, with steady-state concentrations achieved within 3 days of twice daily dosing. Orally administered zafirlukast decreases the bronchoconstrictor effect of inhaled leukotriene D4 (LTD4) in a dose-dependent manner, and reduces the bronchoconstriction induced by cold air, sulphur dioxide, platelet-activating factor or exercise in asthmatic patients. Compared with placebo, zafirlukast reduced allergen-induced bronchoconstriction and the associated bronchial hyperresponsiveness. The action of zafirlukast on the airways has characteristic suggesting it is an antiinflammatory drug. In an initial placebo-controlled study, zafirlukast significantly reduced the cellular infiltrate 48 h after segmental allergen challenge, and reduced superoxide production from purified alveolar macrophages and tumour necrosis factor (TNF)-α concentrations in bronchoalveolar lavage fluid. The pharmacological profile of zafirlukast indicates that it prevents the airflow restriction resulting from bron-choconstriction and other inflammatory changes in the airways and, thus, could be useful as a preventative drug in the management of asthma.

AB - Zafirlukast (Accolate®, ICI-204,219) is a potent and selective antagonist of cysteinyl leukotriene receptors in several animal species, as well as in pulmonary tissues from humans. In animals, it inhibits leukotriene- and antigen-induced bronchoconstriction, plasma extravasation in pulmonary tissue, and eosinophil accumulation in lungs, and attenuates late phase bronchoconstriction and airway hyperresponsiveness following antigen inhalation. In humans, zafirlukast is well absorbed following oral administration, with peak plasma concentrations achieved approximately 3 h postdose. The half-life of zafirlukast is 10 h, with steady-state concentrations achieved within 3 days of twice daily dosing. Orally administered zafirlukast decreases the bronchoconstrictor effect of inhaled leukotriene D4 (LTD4) in a dose-dependent manner, and reduces the bronchoconstriction induced by cold air, sulphur dioxide, platelet-activating factor or exercise in asthmatic patients. Compared with placebo, zafirlukast reduced allergen-induced bronchoconstriction and the associated bronchial hyperresponsiveness. The action of zafirlukast on the airways has characteristic suggesting it is an antiinflammatory drug. In an initial placebo-controlled study, zafirlukast significantly reduced the cellular infiltrate 48 h after segmental allergen challenge, and reduced superoxide production from purified alveolar macrophages and tumour necrosis factor (TNF)-α concentrations in bronchoalveolar lavage fluid. The pharmacological profile of zafirlukast indicates that it prevents the airflow restriction resulting from bron-choconstriction and other inflammatory changes in the airways and, thus, could be useful as a preventative drug in the management of asthma.

KW - Airway responsiveness

KW - Anti-inflammatory

KW - Eosinophils

KW - Late asthmatic response

KW - Leukotriene antagonists

KW - Zafirlukast

UR - http://www.scopus.com/inward/record.url?scp=0030688010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030688010&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 264

EP - 268

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 46

ER -